Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer

Lung Cancer

Volumn 88, Issue 2, 2015, Pages 117-123

  Howell, Matthew ^a   Lee, Rebecca ^a,b   Bowyer, Samantha ^a   Fusi, Alberto ^a   Lorigan, Paul ^a,b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Anti CTLA 4; Anti PD 1; Anti PD L1; Immunotherapy; Lung cancer; Toxicity

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; BILIRUBIN; CHECKPOINT INHIBITOR; DRUG ANTIBODY; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; ANTIBODY; CD274 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

ADRENAL INSUFFICIENCY; AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; COLITIS; DIARRHEA; DRUG ERUPTION; EYE TOXICITY; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOPHYSITIS; HYPOPITUITARISM; HYPOTHYROIDISM; IMMUNOSUPPRESSIVE TREATMENT; LIVER FUNCTION TEST; LUNG CANCER; NEUROPATHY; PANCREATITIS; PATIENT EDUCATION; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIORITY JOURNAL; PRURITUS; REVIEW; VITILIGO; IMMUNOLOGY; LUNG NEOPLASMS;

ANTIBODIES; ANTIGENS, CD274; CTLA-4 ANTIGEN; HUMANS; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84926416165     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.02.007     Document Type: Review

References (50)

1. Sørensen M., Pijls-Johannesma M., Felip E. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v120-v125. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20555060.
2. Crinò L., Weder W., van Meerbeeck J., Felip E. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v103-v115. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20555058.
3. D'Addario G., Früh M., Reck M., Baumann P., Klepetko W., Felip E. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010, 21(Suppl. 5):v116-v119. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20555059.
4. Kim E.S., Hirsh V., Mok T., Socinski M.A., Gervais R., Wu Y.L., et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008, 372(9652):1809-1818. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19027483.
5. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13(3):239-246. Available from: http://www.thelancet.com/journals/a/article/PIIS1470-2045(11)70393-X/fulltext.
6. Shaw A.T., Kim D.-W., Nakagawa K., Seto T., Crinó L., Ahn M.-J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013, 368(25):2385-2394. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23724913.
7. Queirolo P., Spagnolo F., Ascierto P.A., Simeone E., Marchetti P., Scoppola A., et al. Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. J Neurooncol 2014, 118(1):109-116. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4023079&tool=pmcentrez&rendertype=abstract.
8. Ribas A., Hodi F., Kefford R. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL). ASCO annual meeting proceedings 2014, vol. 32:5s.
9. Weber J.S., Minor D.R., D'Angelo S. LBA3_PR - a phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy. ESMO annual meeting 2014.
10. Robert C., Long G.V., Brady B., Dutriaux C., Maio M., Mortier L., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2014, Available from: http://www.ncbi.nlm.nih.gov/pubmed/25399552 [141116004513004].
11. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366:2443-2454.
12. Brahmer J., Horn L., Gandhi L., Spigel D., Antonia J., Rizvi N., et al. Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysis. ASCO meeting abstracts 2014, vol. 32:5s. Available from: http://meetinglibrary.asco.org/content/125774-144.
13. Rizvi N., Garon E., Patnaik A., Gandhi L. Safety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC). ASCO annual meeting proceedings 2014, vol. 32:5s.
14. Wolchok J.D., Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 2008, 13(Suppl. 4):2-9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19001145.
15. Ascierto P.A., Simeone E., Sileni V.C., Pigozzo J., Maio M., Altomonte M., et al. Clinical experience with ipilimumab 3mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med 2014, 12(116). Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4030525&tool=pmcentrez&rendertype=abstract.
16. Ibrahim R., Berman D., DePril V., Humphrey R., Chen T. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. ASCO meeting abstracts 2011, vol. 29. Available from: http://meetinglibrary.asco.org/content/84355-102.
17. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J., Haanen J.B., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23439861.
18. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, (364):2517-2526.
19. Weber J.S., Kähler K.C., Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012, 30(21):2691-2697. Available from: http://jco.ascopubs.org/content/30/21/2691.long.
20. Di Giacomo A.M., Biagioli M., Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010, 37(5):499-507. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21074065.
21. Rizvi N., Scott A., Chow L.Q.M. A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts). ASCO annual meeting abstracts 2013, vol. 31s. Available from: http://meetinglibrary.asco.org/content/113504-132.
22. Brahmer J.R., Tykodi S.S., Chow L.Q.M., Hwu W.-J., Topalian S.L., Hwu P., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012, 366(26):2455-2465. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3563263&tool=pmcentrez&rendertype=abstract.
23. O'Day S.J. A phase III, randomized, double-blind, multicenter study comparing monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma. ASCO annual meeting proceedings 2010.
24. Eggermont A., Chiarion-Sileni V., Grob J., Dummer R., Wolchok J. Ipilimumab versus placebo after complete resection of stage III melanoma: initial efficacy and safety results from the EORTC 18071 phase III trial. J Clin Oncol 2014, 32:5s. Available from: http://meetinglibrary.asco.org/content/130118-144.
25. Gangadhar T.C., Vonderheide R.H. Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol 2014, 11(2):91-99. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24445516.
26. Minor D.R., Chin K., Kashani-Sabet M. Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis. Cancer Biother Radiopharm 2009, 24(3):321-325. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19538054.
27. Weber J., Thompson J.A., Hamid O., Minor D., Amin A., Ron I., et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009, 15(17):5591-5598. Available from: http://clincancerres.aacrjournals.org/content/15/17/5591.abstract?ijkey=7722696b4640b4fea23ca4f02ff518a47e67b76e&keytype2=tf_ipsecsha.
28. Topalian S.L., Sznol M., McDermott D.F., Kluger H.M., Carvajal R.D., Sharfman W.H., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014, 32(10):1020-1030. Available from: http://jco.ascopubs.org/content/32/10/1020.full.
29. Wolchok J.D., Kluger H., Callahan M.K., Postow M., Rizvi N., Lesokhin A.M., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013, 369(2):122-133. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23724867.
30. Hamid O., Robert C., Daud A., Hodi F.S., Hwu W.-J., Kefford R., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013, 369(2):134-144. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23724846.
31. Attia P., Phan G.Q., Maker A.V., et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol 2005, 23(25):6043-6053. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1473965&tool=pmcentrez&rendertype=abstract.
32. Chmiel K.D., Suan D., Liddle C., Nankivell B., Ibrahim R., Bautista C., et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol 2011, 29(9):e237-e240. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21220617.
33. Ribas A., Schadendorf D. Immunotherapy in clinical practice. ESMO annual meeting 2014.
34. Pavlick A.C., Ott P.A., Kannan R., et al. Hair depigmentation as an indicator of durable response to CTLA-4 therapy. ASCO meeting abstracts 2010, vol. 28 (15_suppl):8571. Available from: http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8571.
35. Bristol Myers Squibb Yervoy 2014, Available from: https://www.hcp.yervoy.com/pages/index.aspx.
36. Lynch T.J., Bondarenko I., Luft A., et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012, 30(17):2046-2054. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22547592.
37. Harvey R.D. Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol Ther 2014, 96(2):214-223. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24690569.
38. Chow L.Q.M. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer. Am Soc Clin Oncol Educ Book 2013, Available from: http://www.ncbi.nlm.nih.gov/pubmed/23714523.
39. Gaudy-Marqueste C., Monestier S., Franques J., Cantais E., Richard M.-A., Grob J.-J. A severe case of ipilimumab-induced Guillain-Barré syndrome revealed by an occlusive enteric neuropathy: a differential diagnosis for ipilimumab-induced colitis. J Immunother 2013, 36(1):77-78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23211620.
40. Wilgenhof S., Neyns B. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol 2011, 22(4):991-993. Available from: http://annonc.oxfordjournals.org/content/early/2011/02/28/annonc.mdr028.full.
41. Johnson D.B., Saranga-Perry V., Lavin P.J.M., Burnette W.B., Clark S.W., Uskavitch D.R., et al. Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma. J Clin Oncol 2014, Available from: http://jco.ascopubs.org/content/early/2014/04/28/JCO.2013.51.1683.full.pdf.html.
42. Voskens C.J., Goldinger S.M., Loquai C., Robert C., Kaehler K.C., Berking C., et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 2013, 8(1):e53745. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3544906&tool=pmcentrez&rendertype=abstract.
43. Garon E., Gandhi L., Rizvi N.A. LBA43 - antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC) 2014.
44. Fadel F., El Karoui K., Knebelmann B. Anti-CTLA4 antibody-induced lupus nephritis. N Engl J Med 2009, 361(2):211-212. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19587352.
45. Bhatia S., Huber B.R., Upton M.P., Thompson J.A. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma. J Immunother 2009, 32(2):203-205. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19238020.
46. Tarhini A., LaFramboise W., Petrosko P., Deamont C.G., Kirkwood J.M. Clustered genomic variants specific to patients who develop immune-related colitis after ipilimumab for prediction of toxicity. J Clin Oncol 2014, 32:5s. Available from: http://meetinglibrary.asco.org/content/134015-144.
47. Downey S.G., Klapper J.A., Smith F.O., Yang J.C., Sherry R.M., Royal R.E., et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007, 13(22 Pt 1):6681-6688. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2147083&tool=pmcentrez&rendertype=abstract.
48. Bronstein Y., Ng C.S., Hwu P., Hwu W.-J. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy. AJR Am J Roentgenol 2011, 197(6):W992-W1000. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22109345.
49. Sznol M., Kluger H., Callahan M., Postow M., Gordon R.-A. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol 2014, 32:5s. Available from: http://meetinglibrary.asco.org/content/126008-144 [abstr LBA9003].
50. Robert C., Ribas A., Wolchok J.D., Hodi F.S., Hamid O., Kefford R., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384(9948):1109-1117. Available from: http://www.sciencedirect.com/science/article/pii/S0140673614609582.